Free Trial

Quince Therapeutics (QNCX) Institutional Ownership

Quince Therapeutics logo
$1.78 +0.02 (+1.14%)
(As of 12/20/2024 05:16 PM ET)

Institutional Ownership Changes (13F Filings) for Quince Therapeutics (NASDAQ:QNCX)

Current
Institutional Ownership
Percentage
30.75%
Number of
Institutional Buyers
(last 12 months)
2
Total
Institutional Inflows
(last 12 months)
$146.98K
Number of
Institutional Sellers
(last 12 months)
1
Total
Institutional Outflows
(last 12 months)
$27.15K
Get QNCX Insider Trade Alerts

Want to know when executives and insiders are buying or selling Quince Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

QNCX Institutional Buying and Selling by Quarter

Quince Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024 Geode Capital Management LLC339,125$263K0.0%+24.2%0.784%
8/9/2024 Renaissance Technologies LLC483,902$363K0.0%-7.0%1.120%
1/12/2024 Scharf Investments LLC91,061$96K0.0%N/A0.212%
7/31/2023 Intellectus Partners LLC53,527$81K0.0%N/A0.148%
7/24/2023 BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892%
5/11/2023 EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642%
4/20/2023 Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086%
(Data available from 1/1/2016 forward)

QNCX Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of QNCX shares?

During the previous two years, the following institutional investors and hedge funds held shares of Quince Therapeutics shares: BML Capital Management LLC ($2.13M), EPIQ Capital Group LLC ($1.50M), Renaissance Technologies LLC ($363K), Geode Capital Management LLC ($263K), Scharf Investments LLC ($96K), and Intellectus Partners LLC ($81K), and Hennion & Walsh Asset Management Inc. ($48K).Learn more on QNCX's institutional investors.

What percentage of Quince Therapeutics stock is owned by institutional investors?

30.75% of Quince Therapeutics stock is owned by institutional investors. Learn more on QNCX's institutional investor holdings.

Which institutional investors have been buying Quince Therapeutics stock?

The following institutional investors have purchased Quince Therapeutics stock in the last 24 months: BML Capital Management LLC ($1.41M), Scharf Investments LLC ($91.06K), Geode Capital Management LLC ($66.17K), Intellectus Partners LLC ($53.53K), and Hennion & Walsh Asset Management Inc. ($31.06K).

How much institutional buying is happening at Quince Therapeutics?

Institutional investors have bought a total of 1,653,658 shares in the last 24 months. This purchase volume represents approximately $2.40M in transactions.

Which Quince Therapeutics major shareholders have been selling company stock?

The following institutional investors have sold Quince Therapeutics stock in the last 24 months: EPIQ Capital Group LLC ($97.72K), and Renaissance Technologies LLC ($36.20K).

How much institutional selling is happening at Quince Therapeutics?

Institutional investors have sold a total of 133,920 shares in the last 24 months. This volume of shares sold represents approximately $179.59K in transactions.



This page (NASDAQ:QNCX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners